Health sciences

Radius Health Business Update

Tuesday, July 27, 2021 - 1:00pm

To date in 2021, 80+% of our top 50 TYMLOS prescribers are fracture / bone health focused, a trend we see accelerating.

Key Points: 
  • To date in 2021, 80+% of our top 50 TYMLOS prescribers are fracture / bone health focused, a trend we see accelerating.
  • Radius plans to move forward with a seamless Phase 2/3 pivotal trial for PWS.
  • Radius goal: through the pivotal trial and subsequent data readout, demonstrate efficacy and safety for FDA approval, and to help patients living with PWS.
  • Radius is a commercial biopharmaceutical company committed to serving patients with unmet medical needs in endocrinology and other therapeutic areas.

Antibe Therapeutics Provides July 2021 Corporate Update

Tuesday, July 27, 2021 - 12:00pm

Antibe is taking a comprehensive approach to maximizing the likelihood of a successful Phase III program outcome.

Key Points: 
  • Antibe is taking a comprehensive approach to maximizing the likelihood of a successful Phase III program outcome.
  • The program also combines several state-of-the-art aspects, including the hiring of leading providers of bioanalytic, quality control and data management services.
  • The latter will enable us to track and manage screening and enrollment in real-time, ensuring that the subject population matches trial criteria.
  • Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

Tuesday, July 27, 2021 - 12:35pm

The study comparing REL-1017 to oxycodone is the first of two clinical trials to assess abuse potential per FDA guidance as part of the planned REL-1017 NDA for the treatment of MDD.

Key Points: 
  • The study comparing REL-1017 to oxycodone is the first of two clinical trials to assess abuse potential per FDA guidance as part of the planned REL-1017 NDA for the treatment of MDD.
  • The scheduling of a drug depends on the analysis of several parameters (receptor studies, animal studies, human studies, history of abuse).
  • Oxycodone, the active control, was administered at the dose of 40 mg, a standard dose in HAP studies.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

iXensor Levels Up PixoTest Covid-19 Ag Test With The Launch Of PixoHealth Data Management Platform As The Security Solution For The New Normalcy

Tuesday, July 27, 2021 - 12:32pm

In addition, the PixoHealth Pass Admin Web Portal synchronizes multi-source COVID-19 related health data and rapid test results from PixoHealth Pass App users and PixoTest POCT Analyzer simultaneously.

Key Points: 
  • In addition, the PixoHealth Pass Admin Web Portal synchronizes multi-source COVID-19 related health data and rapid test results from PixoHealth Pass App users and PixoTest POCT Analyzer simultaneously.
  • The utilization of PixoHealth Pass Admin Web Portal, PixoTest POCT Analyzer and PixoHealth Pass App fully digitizes the data management processes with a one-time setup.
  • In addition, PixoHealth Pass Admin App allows organizations to configure health-data based access management rules for keeping SARS-CoV-2 from causing cluster infections.
  • In 2017, iXensor introduced the PixoTest Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test.

Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update

Tuesday, July 27, 2021 - 12:30pm

(Nasdaq:RIGL) today announced that it will report its second quarter 2021 financial results after market close on Tuesday, August 3, 2021.

Key Points: 
  • (Nasdaq:RIGL) today announced that it will report its second quarter 2021 financial results after market close on Tuesday, August 3, 2021.
  • Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business.
  • In addition, Rigel has product candidates in development with partners AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.
  • 1The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.

Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity

Tuesday, July 27, 2021 - 12:00pm

As published in Science , the new target was found by sequencing nearly 650,000 people and identifying individuals with rare protective mutations.

Key Points: 
  • As published in Science , the new target was found by sequencing nearly 650,000 people and identifying individuals with rare protective mutations.
  • "As experts on genetics and human biology, Regeneron is excited to join forces with the chemistry and small molecule leaders at AstraZeneca, as we seek to develop new medicines tackling the harmful and costly obesity epidemic."
  • "We are pleased to announce this important collaboration with Regeneron to identify small molecule modulators against GPR75, a newly identified target with genetic validation in metabolic disorders.
  • Worldwide the prevalence of obesity has more than tripled since 1975, and approximately 650 million adults are estimated to live with obesity today.

Day One Receives FDA Rare Pediatric Disease Designation for DAY101 for the Treatment of Pediatric Low-Grade Glioma

Tuesday, July 27, 2021 - 12:00pm

In addition to FDA Rare Pediatric Disease Designation, DAY101 has been granted Breakthrough Therapy designation by the FDA for the treatment of patients with pLGG harboring an activating RAF alteration who require systemic therapy and who have either progressed following prior treatment or who have no satisfactory alternative treatment options.

Key Points: 
  • In addition to FDA Rare Pediatric Disease Designation, DAY101 has been granted Breakthrough Therapy designation by the FDA for the treatment of patients with pLGG harboring an activating RAF alteration who require systemic therapy and who have either progressed following prior treatment or who have no satisfactory alternative treatment options.
  • In addition, DAY101 has received Orphan Drug designation from the FDA for the treatment of malignant glioma and orphan designation from the European Commission for the treatment of glioma.
  • The FDA has also granted Rare Pediatric Disease Designation to DAY101 for the treatment of low-grade gliomas harboring an activating RAF alteration that disproportionately affects children.
  • In addition, DAY101 has received Orphan Drug designation from the FDA for the treatment of malignant glioma and orphan designation from the European Commission for the treatment of glioma.

Global Medical Marijuana Market to 2027 - ResearchAndMarkets.com

Tuesday, July 27, 2021 - 11:15am

The "Global Medical Marijuana Market to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Medical Marijuana Market to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Increase in awareness regarding various medical applications such as appetite enhancement, pain management, and reducing eye pressure is the key driving factor which is expected to boost the global medical marijuana market growth.
  • However, Medical marijuana is not approved by USFDA (Food and Drug Administration) for the treatment of cancer which is major restraining factor which is expected to hamper the global medical marijuana market growth.
  • Global Medical Marijuana Market is segmented into route of administration such as Oral, Inhalation, and Topical.

Insights on the Pulmonary/ Respiratory Drug Delivery Global Market to 2027 - Featuring 3M, Cipla and Omron Among Others - ResearchAndMarkets.com

Tuesday, July 27, 2021 - 9:49am

The "Pulmonary/ Respiratory Drug Delivery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pulmonary/ Respiratory Drug Delivery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. Market is Estimated at $12.5 Billion, While China is Forecast to Grow at 4.8% CAGR
    The Pulmonary/ Respiratory Drug Delivery market in the U.S. is estimated at US$12.5 Billion in the year 2020.
  • In the global Nebulizer segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.9 Billion by the year 2027.

U.S. Retractable Needle Safety Syringes Market Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028 - ResearchAndMarkets.com

Tuesday, July 27, 2021 - 9:47am

The "U.S. Retractable Needle Safety Syringes Market, by Product Type, by End User, and by Distribution Channel - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Retractable Needle Safety Syringes Market, by Product Type, by End User, and by Distribution Channel - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • A needle is a solid and slender instrument, which is pointed at the end and is designed for puncturing of tissues.
  • Safety needles have a safety mechanism built into the needles to protect healthcare workers and others from accidental needlestick injuries.
  • Rising prevalence of gynecologic cancer and spine disorders, government initiatives for blood collection and favorable reimbursement for pen needles are some of the major factors responsible for the growth of the U.S. retractable needle safety syringes market.